课题基金 / 基金详情

EASTERN COOPERATIVE ONCOLOGY GROUP

EASTERN COOPERATIVE ONCOLOGY GROUP
东方肿瘤合作组
批准号:
2099890
负责人:
CARLA I FALKSON
金额:
$5.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-08-08 至 1997-04-30

项目摘要

项目成果

CARLA I FALKSON的其他基金

相似基金

相关文献

中文摘要
翻译
描述:比勒陀利亚大学自1972年以来一直是ECOG的成员, 正在请求支持,以促进继续参加西非经共体。作为 作为ECOG的成员,该机构正在努力改善 癌症患者的生活质量和持续时间, 科学地评估最有效的治疗方案, 癌症的类型和阶段 该方案的具体目标是:(1) 在所有ECOG中保持完全可评价患者的高入组率 治疗和非治疗方案;(2)维持和完善 有效的数据管理计划;(3)继续为 制定创新的治疗方案并继续发挥领导作用 在ECOG的科学计划中;(4)公布ECOG的结果 (5)继续提供收集到的科学信息 (6)在国家和国际会议上, 到ECOG和NCI的肝细胞癌,食道癌, 和间皮瘤,这所机构有独特的资源。 来自比勒陀利亚大学的调查人员主持或曾主持过 在不同疾病领域的多项ECOG研究。 其中包括恶性 黑色素瘤、乳腺癌、原发性肝癌、间皮瘤和 食道癌
英文摘要
DESCRIPTION: The University of Pretoria, a member of ECOG since 1972, is requesting support to facilitate continued participation in ECOG. As a member of ECOG, this institution is attempting to improve both the quality and duration of cancer patients' lives by developing and scientifically evaluating the most effective treatment programs for all types and stages of cancer. The specific aims of this program are: (1) to maintain a high accrual rate of fully evaluable patients on all ECOG therapeutic and non-therapeutic protocols; (2) to maintain and refine an effective data management program; (3) to continue contribution to the development of innovative treatment protocols and continue leadership in the scientific programs of ECOG; (4) to publish results of ECOG studies; (5) to continue to present the scientific information gathered by ECOG at national and international meetings; and (6) to contribute to ECOG and NCI programs on hepatocellular carcinoma, esophagus cancer, and mesothelioma where this institution has unique resources. Investigators from the University of Pretoria chair or have chaired several ECOG studies in various disease areas. These include malignant melanoma, breast cancer, primary liver cancer, mesothelioma, and esophagus cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
E2104 TRIAL OF AVASTIN DD ADRIAMYCIN AND CYTOXAN FOLLOWED BY TAXOL IN LYMPH NODE
UAB 0461 BEVACIZUMAB TO REVERSE ACQUIRED ESTROGEN INDEPENDENCE IN BREAST CANCER
Phase III chemoprevention trial with selenium in NSCLC
High dose interferon vs observation in st. 3-4 melanoma
海外基金